Loading...

The ethical dilemma of Pureco Corporation: should it sell the harmful Newpen antibiotics abroad?

1. Introduction

Antibiotics are vital in the fight against life-threatening diseases. They have been used for over 70 years and have saved millions of lives. However, the overuse and misuse of antibiotics has led to the development of antibiotic resistance, which is when bacteria becomes resistant to the effects of an antibiotic.

According to the World Health Organization (WHO), antibiotic resistance is one of the biggest threats to global health, food security, and development today. The WHO estimates that without action, antibiotic resistance will cause 10 million deaths annually by 2050.

One company that is facing an ethical dilemma related to antibiotics is Pureco Corporation. The company has developed a new antibiotic called Newpen, which it plans to sell in the United States. However, the United States Food and Drug Administration (FDA) has not yet approved Newpen for use in humans.

The FDA is concerned about the potential side effects of Newpen and has asked Pureco to conduct additional safety testing. However, Pureco is already facing financial difficulties and cannot afford to conduct the additional testing. As a result, Pureco is considering selling Newpen to foreign countries where it does not need FDA approval.

2. The ethical dilemma of Pureco Corporation

The ethical dilemma facing Pureco Corporation is whether to sell the harmful Newpen antibiotics abroad to recover the already invested amount. On one hand, if Pureco sells Newpen without FDA approval, it could potentially save lives by providing a much-needed antibiotic. On the other hand, selling an unapproved drug could put people’s health at risk and damage Pureco’s reputation.

There are three potential solutions to this dilemma: 1) Sell Newpen without FDA approval; 2) Conduct additional safety testing; or 3) Do nothing and hope that the FDA approves Newpen eventually. Each solution has its own risks and benefits that must be considered before a decision is made.

3. The potential impacts of selling Newpen abroad

If Pureco decides to sell Newpen without FDA approval, there are several potential impacts that could occur. First, it is possible that some people who take Newpen could experience serious side effects such as allergic reactions, kidney damage, or death. Second, selling an unapproved drug could damage Pureco’s reputation and make it difficult to sell other products in the future. Third, Pureco could be subject to legal action from the FDA or other government agencies.

4. The possible solutions to the dilemma

There are three possible solutions to the dilemma facing Pureco Corporation: 1) Sell Newpen without FDA approval; 2) Conduct additional safety testing; or 3) Do nothing and hope that the FDA approves Newpen eventually.

If Pureco decides to sell Newpen without FDA approval, it should do so with caution. Pureco should only sell Newpen to countries where it can be closely monitored and where there is a high need for new antibiotics. In addition, Pureco should make sure that patients are aware of the risks associated with taking Newpen before they decide to take it.

If Pureco decides to conduct additional safety testing, it should do so as quickly as possible so that it can get FDA approval and start selling Newpen in the United States. In addition, Pureco should make sure that the additional safety testing is thorough and that all potential risks are considered.

If Pureco decides to do nothing and hope that the FDA approves Newpen eventually, it is possible that the FDA may never approve Newpen. In addition, waiting for FDA approval could put people’s health at risk in the meantime. As a result, this solution should only be used as a last resort.

5. Conclusion

The ethical dilemma facing Pureco Corporation is whether to sell the harmful Newpen antibiotics abroad to recover the already invested amount. On one hand, if Pureco sells Newpen without FDA approval, it could potentially save lives by providing a much-needed antibiotic. On the other hand, selling an unapproved drug could put people’s health at risk and damage Pureco’s reputation.

There are three potential solutions to this dilemma: 1) Sell Newpen without FDA approval; 2) Conduct additional safety testing; or 3) Do nothing and hope that the FDA approves Newpen eventually. Each solution has its own risks and benefits that must be considered before a decision is made.

FAQ

Pureco Corporation was motivated to develop an ethical dilemma in order to create a more ethical workplace environment. The company felt that by implementing an ethical dilemma, employees would be more likely to act ethically and make better decisions.

Pureco Corporation researched and developed their ethical dilemma by looking at other companies that had implemented similar programs. They also consulted with experts in the field of ethics to ensure that their program was well-rounded and would be effective.

Some of the potential benefits of implementing an ethical dilemma within the company include increased employee morale, improved decision making, and reduced unethical behavior.

There are some risks associated with implementing an ethical dilemma within the company, such as the potential for employees to abuse the system or misuse it for personal gain. However, these risks can be mitigated through proper training and communication with employees.

If you were in Pureco Corporation's position, you would resolve the ethical dilemma by developing a clear set of guidelines for employees to follow when faced with an ethical issue. These guidelines would help employees to make the right decision in any given situation.

The most important thing for companies to consider when developing and implementing an ethical dilemma is how it will impact all stakeholders involved. It is important to consider the needs of both employees and customers when making decisions about ethics in the workplace

Cite this assignment

Free Essay Samples (February 5, 2023) The ethical dilemma of Pureco Corporation: should it sell the harmful Newpen antibiotics abroad?. Retrieved from https://essayholic.com/the-ethical-dilemma-of-pureco-corporation-should-it-sell-the-harmful-newpen-antibiotics-abroad/.
"The ethical dilemma of Pureco Corporation: should it sell the harmful Newpen antibiotics abroad?." Free Essay Samples - February 5, 2023, https://essayholic.com/the-ethical-dilemma-of-pureco-corporation-should-it-sell-the-harmful-newpen-antibiotics-abroad/
Free Essay Samples June 11, 2022 The ethical dilemma of Pureco Corporation: should it sell the harmful Newpen antibiotics abroad?., viewed February 5, 2023,<https://essayholic.com/the-ethical-dilemma-of-pureco-corporation-should-it-sell-the-harmful-newpen-antibiotics-abroad/>
Free Essay Samples - The ethical dilemma of Pureco Corporation: should it sell the harmful Newpen antibiotics abroad?. [Internet]. [Accessed February 5, 2023]. Available from: https://essayholic.com/the-ethical-dilemma-of-pureco-corporation-should-it-sell-the-harmful-newpen-antibiotics-abroad/
"The ethical dilemma of Pureco Corporation: should it sell the harmful Newpen antibiotics abroad?." Free Essay Samples - Accessed February 5, 2023. https://essayholic.com/the-ethical-dilemma-of-pureco-corporation-should-it-sell-the-harmful-newpen-antibiotics-abroad/
"The ethical dilemma of Pureco Corporation: should it sell the harmful Newpen antibiotics abroad?." Free Essay Samples [Online]. Available: https://essayholic.com/the-ethical-dilemma-of-pureco-corporation-should-it-sell-the-harmful-newpen-antibiotics-abroad/. [Accessed: February 5, 2023]

More Related papers

Top